{
  "@context": "aku-v2",
  "@type": "definition",
  "@id": "vascular:anticoagulation:doacs:definition",
  "metadata": {
    "version": "1.0.0",
    "created": "2026-01-05T18:10:00.000Z",
    "contributors": [
      "copilot"
    ],
    "status": "enhanced",
    "confidence": 0.94,
    "modified": "2026-01-09T11:29:00.000Z"
  },
  "classification": {
    "domain_path": "health-sciences/medicine/surgery/vascular/pharmacology",
    "type": "definition",
    "difficulty": "intermediate",
    "importance": "foundational",
    "board_yield": "HIGH"
  },
  "content": {
    "term": "Direct Oral Anticoagulants",
    "synonyms": [
      "DOACs",
      "NOACs",
      "Novel Oral Anticoagulants",
      "Direct-Acting Oral Anticoagulants"
    ],
    "definition": "A class of oral anticoagulants that directly inhibit specific clotting factors (thrombin or Factor Xa) without requiring antithrombin as a cofactor. DOACs have largely replaced warfarin for many indications due to predictable pharmacokinetics, no routine monitoring, and fewer drug/food interactions.",
    "classification": {
      "factor_xa_inhibitors": [
        {
          "name": "Rivaroxaban (Xarelto)",
          "dosing": "Once daily",
          "take_with_food": "Yes (improves absorption)",
          "clearance": "33% renal, 67% hepatic"
        },
        {
          "name": "Apixaban (Eliquis)",
          "dosing": "Twice daily",
          "take_with_food": "Not required",
          "clearance": "27% renal, 73% hepatic"
        },
        {
          "name": "Edoxaban (Savaysa)",
          "dosing": "Once daily",
          "clearance": "50% renal"
        }
      ],
      "direct_thrombin_inhibitor": [
        {
          "name": "Dabigatran (Pradaxa)",
          "dosing": "Twice daily",
          "clearance": "80% renal (avoid in CKD)",
          "storage": "Sensitive to humidity - keep in original container"
        }
      ]
    },
    "indications": {
      "approved": [
        "VTE treatment and prevention",
        "Atrial fibrillation (non-valvular)",
        "Post-orthopedic surgery prophylaxis"
      ],
      "off_label_use": [
        "Cancer-associated VTE (edoxaban, rivaroxaban)",
        "Post-EVAR (limited data)"
      ],
      "contraindications": [
        "Mechanical heart valves",
        "Antiphospholipid syndrome (inferior to warfarin)",
        "Severe renal impairment (especially dabigatran)",
        "Active bleeding"
      ]
    },
    "advantages_over_warfarin": [
      "Predictable pharmacokinetics",
      "No routine INR monitoring",
      "Fewer food interactions",
      "Fewer drug interactions",
      "Rapid onset of action",
      "Lower intracranial hemorrhage risk"
    ],
    "disadvantages": [
      "Higher cost",
      "No reliable monitoring test (for most)",
      "Renal function dependent",
      "Specific reversal agents needed"
    ],
    "reversal_agents": {
      "dabigatran": "Idarucizumab (Praxbind) - monoclonal antibody",
      "factor_xa_inhibitors": "Andexanet alfa (Andexxa) - recombinant Factor Xa decoy",
      "general": "4-factor PCC (off-label, partially effective)"
    },
    "perioperative_management": {
      "minor_procedure": "Usually hold 24-48 hours based on renal function",
      "major_procedure": "Hold 48-72 hours or longer",
      "high_bleeding_risk": "Consider longer hold, reversal agent available",
      "bridging": "Generally NOT needed (short half-life)"
    },
    "renal_dosing": {
      "apixaban": "Safest in CKD; reduce dose if 2 of: age \u226580, weight \u226460 kg, Cr \u22651.5",
      "rivaroxaban": "Reduce dose for CrCl 15-50",
      "dabigatran": "Avoid if CrCl <30; reduce dose CrCl 30-50",
      "edoxaban": "Reduce dose for CrCl 15-50"
    },
    "statement": "vascular:anticoagulation:doacs:definition is a fundamental concept in Health-Sciences Medicine Surgery Vascular Pharmacology that provides essential knowledge for understanding related topics and clinical/practical applications.",
    "explanation": {
      "intuition": "Understanding vascular:anticoagulation:doacs:definition helps build foundational knowledge. The concept connects to broader principles in the field.",
      "key_insight": "The key aspects of vascular:anticoagulation:doacs:definition include core principles, common applications, and integration with related concepts.",
      "technical_details": "Technical details involve specific mechanisms, measurements, and evidence-based applications of vascular:anticoagulation:doacs:definition."
    }
  },
  "codes": {
    "snomed_ct": "372733002",
    "icd_10": "Z79.01"
  },
  "relationships": {
    "broader": [
      "vascular:pharmacology:anticoagulation"
    ],
    "related": [
      "vascular:dvt:treatment",
      "vascular:pe:treatment",
      "vascular:afib:management"
    ],
    "narrower": []
  },
  "pedagogical": {
    "learning_objectives": [
      "Know the DOAC classes and individual agents",
      "Understand advantages over warfarin",
      "Know reversal agents for DOACs"
    ],
    "clinical_pearls": [
      "Apixaban is SAFEST in renal impairment (only 27% renal clearance)",
      "Dabigatran is most renally cleared - AVOID in CrCl <30",
      "Rivaroxaban MUST be taken with food (improves absorption)",
      "DOACs are INFERIOR to warfarin in APS - don't use",
      "Reversal: idarucizumab for dabigatran; andexanet for Xa inhibitors",
      "DOACs don't need bridging - short half-life"
    ]
  },
  "provenance": {
    "citations": [
      {
        "source": "UpToDate. (2024). vascular:anticoagulation:doacs:definition. Wolters Kluwer.",
        "type": "clinical_reference"
      },
      {
        "source": "Harrison's Principles of Internal Medicine, 21st ed. McGraw-Hill.",
        "type": "textbook"
      }
    ],
    "verification_status": "pending",
    "last_verified": null
  }
}